Kim Christopher, Chairman and CMO of Apimeds Pharmaceuticals US, Inc. ($APUS), made two open market purchases of $APUS stock in the past year, totaling $50,359. His latest buy occurred on May 14, 2025. With no sales reported, his activity ranks 2,971st out of nearly 5,000 insiders, below the average purchase of $1.5 million across 3.3 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct. 15, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Kim Christopher | Chairman and CMO | A | Stock Option (right to buy) | 3000 | $0.00 | 3,000.0000 | 12,575,983 | 9999.99% | 0.02% |
| May 16, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Kim Christopher | Chairman and CMO | A | Common Stock, par value $0.01 per share | 250000 | $0.00 | 277,500.0000 | 7,903,850 | 909.09% | 3.16% |
| May 13, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Kim Christopher | Chairman and CMO | P | Common Stock, par value $0.01 per share | 19770 | $1.82 | 19,770.0000 | 7,903,850 | 9999.99% | 0.25% |
| May 14, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Kim Christopher | Chairman and CMO | P | Common Stock, par value $0.01 per share | 7730 | $1.86 | 27,500.0000 | 7,903,850 | 39.10% | 0.10% |